CHMP recommends new formulation of pegaspargase

Micrograph showing ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorization for lyophilized pegaspargase (ONCASPAR). If approved, the product would be used as a component of antineoplastic therapy in patients of all ages who have acute lymphoblastic leukemia (ALL). The product is a freeze-dried formulation of liquid pegaspargase, which is already approved for the aforementioned indication. The CHMP’s recommendation regarding lyophilized pegaspargase will be submitted to the European Commission (EC). [Read Article]

Cryotherapy can reduce signs of CIPN

Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
A new study suggests cryotherapy can reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Researchers found that having chemotherapy patients wear frozen gloves and socks for 90-minute periods significantly reduced the incidence of CIPN symptoms. Hiroshi Ishiguro, MD, PhD, of International University of Health and Welfare Hospital in Tochigi, Japan, and colleagues reported these findings in the Journal of the National Cancer Institute. [Read Article]

Natural selection opportunities tied to cancer rates

Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural selection, according to a study published in Evolutionary Applications. Researchers said this is because modern medicine is enabling people to survive cancers, and their genetic backgrounds are passing from one generation to the next. The team said the rate of some cancers has doubled and even quadrupled over the past 100 to 150 years, and human evolution has moved away from “survival of the fittest.” [Read Article]